Dosing & Administration for Migraine

Emgality offers a once-monthly, self-administered subcutaneous injection¹

The Emgality Pen¹:

Once-monthly dosing
No titration required
Latex-free

Recommended dosing with no titration required^1a

Month 1: Initial loading dose of two 120 mg injections
Subsequent months: One 120 mg injection per month

A loading dose of 240 mg resulted in steady-state Emgality concentrations after the first dose.¹

With the Emgality loading dose, 15% of patients’ first-year therapy is administered on Day 1.^1b

^aThe Emgality Pen needle is 27 gauge x 1/2 inch.²

^bCalculation: 240 mg loading dose + 120 mg/month x 11 months=1560 mg; 240 mg/1560 mg=0.1538 (15%).¹

See Emgality Dosing for Patients With Episodic Cluster Headache

Indications and Important Safety Information

Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

Preventive treatment of migraine
Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 04JUN2019

^aTerms and Conditions:

By using the Emgality Savings Card (“Card”), you attest that you meet the eligibility criteria and will comply with the Terms and Conditions described below:

Offer good for up to 12 months until 12/31/2020 if healthcare provider submits the prior authorization form or letter of medical necessity, if required, to the patient’s insurance provider. $0 monthly offer for commercially insured with insurance provider coverage, subject to wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual cap. $0 monthly offer for commercially insured without insurance provider coverage, subject to monthly and annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps.

Offer void where prohibited by law. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE/CHAMPUS, or any state patient or pharmaceutical assistance program. If you live in Massachusetts, the Card expires on the earlier of: (i) the expiration date of this Card (12/31/2020); (ii) the date an AB-rated generic equivalent for Emgality becomes available; or (iii) December 31, 2019, absent a change in Massachusetts state law. If you live in California, the Card expires on the earlier of: (i) the expiration date of this Card (12/31/2020) or (ii) the date an FDA-approved therapeutically equivalent for Emgality or over-the-counter product with the same active ingredients becomes available.

Available only in the US and Puerto Rico for residents of the US and Puerto Rico. By accepting this offer, you agree that if you are required to do so under the terms of your insurance coverage for this prescription or are otherwise required to do so by law, you should notify your insurance carrier of your redemption of this Card. This offer cannot be combined or utilized with any other program, discount, discount card, incentive, or similar offer involving Emgality. It is prohibited for any person to sell, purchase, or trade; or to offer to sell, purchase, or trade; or to counterfeit this Card. This offer may be terminated, rescinded, revoked, or amended by Lilly USA, LLC at any time without notice. Card activation required. This Card is not health insurance. This Card expires on 12/31/2020.

Dosing & Administration for Migraine

Emgality offers a once-monthly, self-administered subcutaneous injection1

The Emgality Pen1:

Recommended dosing with no titration required1a